HK1211525A1 - Laquinimod and pridopidine for treating neurodegenerative disorders - Google Patents

Laquinimod and pridopidine for treating neurodegenerative disorders Download PDF

Info

Publication number
HK1211525A1
HK1211525A1 HK15112317.4A HK15112317A HK1211525A1 HK 1211525 A1 HK1211525 A1 HK 1211525A1 HK 15112317 A HK15112317 A HK 15112317A HK 1211525 A1 HK1211525 A1 HK 1211525A1
Authority
HK
Hong Kong
Prior art keywords
pridopidine
laquinimod
treating
neurodegenerative disorders
neurodegenerative disorder
Prior art date
Application number
HK15112317.4A
Other languages
English (en)
Chinese (zh)
Inventor
Hayden Michael
Bar-Zohar Dan
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1211525A1 publication Critical patent/HK1211525A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Mechanical Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15112317.4A 2012-09-27 2013-09-27 Laquinimod and pridopidine for treating neurodegenerative disorders HK1211525A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261706695P 2012-09-27 2012-09-27
US61/706,695 2012-09-27
US201361879004P 2013-09-17 2013-09-17
US61/879,004 2013-09-17
PCT/US2013/062482 WO2014052933A1 (en) 2012-09-27 2013-09-27 Laquinimod and pridopidine for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
HK1211525A1 true HK1211525A1 (en) 2016-05-27

Family

ID=50339469

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15112317.4A HK1211525A1 (en) 2012-09-27 2013-09-27 Laquinimod and pridopidine for treating neurodegenerative disorders
HK16102362.8A HK1214553A1 (zh) 2012-09-27 2013-09-27 用於治疗神经退行性疾病的拉喹莫德和普利多匹定

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16102362.8A HK1214553A1 (zh) 2012-09-27 2013-09-27 用於治疗神经退行性疾病的拉喹莫德和普利多匹定

Country Status (13)

Country Link
US (7) US20140088140A1 (enExample)
EP (1) EP2900330A4 (enExample)
CN (1) CN104902958A (enExample)
AU (1) AU2013323131A1 (enExample)
BR (1) BR112015006623A2 (enExample)
CA (1) CA2884781A1 (enExample)
EA (1) EA201590655A8 (enExample)
HK (2) HK1211525A1 (enExample)
IL (1) IL237742A0 (enExample)
IN (1) IN2015DN03219A (enExample)
MX (1) MX2015003608A (enExample)
WO (1) WO2014052933A1 (enExample)
ZA (1) ZA201502600B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2008127188A1 (en) * 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CA2847736A1 (en) 2011-09-07 2013-03-14 IVAX International GmbH A new polymorphic form of pridopidine hydrochloride
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
SG11201509729YA (en) 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EP3082814A4 (en) * 2013-12-20 2017-06-21 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay huntington's disease progression
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2961187A1 (en) * 2014-09-16 2016-03-24 Teva Pharmaceuticals Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
MX378579B (es) * 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CA2993183A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
PL3570940T3 (pl) 2017-01-20 2024-06-17 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x
US11253594B2 (en) 2017-07-07 2022-02-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Drug combinations for protecting against neuronal cell death
EP4620471A3 (en) * 2017-08-14 2025-11-26 Prilenia Neurotherapeutics Ltd. Treating amyotrophic lateral sclerosis with pridopidine
MX2021011269A (es) * 2019-03-15 2021-10-01 Prilenia Neurotherapeutics Ltd Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
HRP20260072T1 (hr) * 2019-06-12 2026-02-27 Prilenia Neurotherapeutics Ltd. Supstanca koja obuhvaća pridopidin i njegov analog za liječenje huntingtonove bolesti i njezinih simptoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528040T3 (es) * 2007-06-18 2015-02-03 A.Carlsson Research Ab Uso de estabilizadores de dopamina
CA2743717A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
AU2010282948C1 (en) * 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
MX2013006464A (es) * 2010-12-07 2013-07-29 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple.

Also Published As

Publication number Publication date
US20190117639A1 (en) 2019-04-25
US20180133209A1 (en) 2018-05-17
HK1214553A1 (zh) 2016-07-29
EP2900330A4 (en) 2016-05-25
EP2900330A1 (en) 2015-08-05
IL237742A0 (en) 2015-05-31
US20180250285A1 (en) 2018-09-06
US20180369228A1 (en) 2018-12-27
EA201590655A1 (ru) 2015-12-30
CA2884781A1 (en) 2014-04-03
BR112015006623A2 (pt) 2017-07-04
EA201590655A8 (ru) 2016-07-29
CN104902958A (zh) 2015-09-09
IN2015DN03219A (enExample) 2015-10-02
WO2014052933A1 (en) 2014-04-03
MX2015003608A (es) 2015-06-05
AU2013323131A1 (en) 2015-05-07
US20170319569A1 (en) 2017-11-09
US20140088140A1 (en) 2014-03-27
US20150209346A1 (en) 2015-07-30
ZA201502600B (en) 2016-06-29

Similar Documents

Publication Publication Date Title
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
HK1211483A1 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX394909B (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos
WO2012103038A9 (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2013061161A3 (en) New combination therapies for treating neurological disorders
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
WO2014031610A8 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2012062925A3 (en) Compounds and methods for treating pain
HK1199820A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
HK1205941A1 (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
WO2013188847A8 (en) Compositions and methods for transmucosal absorption
WO2014037416A3 (en) Compositions for treating parkinson's disease
BR112012022552A2 (pt) uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
HK1217092A1 (zh) 治疗性化合物及其用途
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
IL260078B (en) Therapy used to treat Gaucher disease
HK1218251A1 (zh) 用拉喹莫德治疗多发性硬化症
HUE038580T2 (hu) Hatóanyag bejuttató rendszer neurológiai rendellenességek kezelésében, vagy diagnózisában való felhasználásra
HK1209672A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine
HUE037689T2 (hu) Pirazol-karboxamid származékok mint TAAR-modulátorok különféle rendellenességek, mint például depresszió, cukorbetegség és Parkinson-kór kezelésében történõ alkalmazásra
HK1225972A1 (zh) 利用拉喹莫德来延缓亨廷顿氏病的进展
HK1222585A1 (zh) 用於提供疼痛减轻和麻醉的二氢埃托啡